For U.S. Residents Only

Sanofi OncologySanofi Oncology
Prescribing Information
Mozobil

Prescribing Information
Important Safety Information

Mozobil
Search:
1-877-4MOZOBIL
(1-877-466-9624)

Important Safety Information for Mozobil (plerixafor injection)
Severe, life-threatening allergic reactions (anaphylaxis) can happen in people who take Mozobil. Tell your doctor right away if you experience hives (itchy raised bumps), eye swelling, or trouble breathing. View additional Important Safety Information.

Questions to Ask Your Doctor

Learning about your treatment is an important part of the fight against your disease. By asking questions you can work together with your doctor and transplant team to ensure you are kept informed about your disease and treatment.

Review the questions below.* It may be helpful to print these questions and take them with you to your next appointment so you can discuss them with your healthcare team.

Hematopoietic Stem Cell Transplant

Do I need to undergo a stem cell transplant?
Why do I need a stem cell transplant?
Will I be undergoing an autologous stem cell transplant (donating my own stem cells for use in transplant)?

Autologous Stem Cell Transplant

When will I undergo a stem cell transplant?
How should I prepare for a stem cell transplant?
What specific instructions should I follow during a stem cell transplant?
What side effects can I expect from a stem cell transplant?

Stem Cell Mobilization

What kind of stem cell mobilization regimen will I be undergoing?
How should I prepare for stem cell mobilization?
What specific instructions should I follow during my mobilization regimen?
What side effects can I expect from my mobilization regimen?

Stem Cell Collection

When will my stem cells be collected?
How should I prepare for stem cell collection?
What specific instructions should I follow during stem cell collection?
What side effects can I expect from stem cell collection?

Engraftment and Recovery

How long will it take for my infused stem cells to mature and produce healthy new blood cells (engraftment)?
What do I need to do to protect my health until engraftment occurs?
How will I feel after engraftment occurs?

Take these questions with you to your next appointment:

Download and print questions (PDF)

* This is not a complete list of possible questions, and should not be considered medicial advice. Please consult with your healthcare team.

Indication

Mozobil (plerixafor injection) is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM).

Important Safety Information for Mozobil (plerixafor injection)

  • Severe, life-threatening allergic reactions (anaphylaxis) can happen in people who take Mozobil. Tell your doctor right away if you experience hives (itchy raised bumps), eye swelling, or trouble breathing.
  • Mozobil is not intended for hematopoietic stem cell transplantation (HSCT) mobilization and collection in patients with leukemia.
  • Mozobil in combination with G-CSF increases circulating white blood cells (WBCs). Your WBC counts will be monitored.
  • Thrombocytopenia (a decrease in the number of platelets circulating in the blood) has been observed in patients receiving Mozobil. Your platelet counts will be monitored.
  • Cancer cells may be released from the bone marrow and subsequently collected along with your stem cells during apheresis. The potential effects of infusing cancer cells during your transplant have not been well-studied.
  • Your spleen may be examined if you experience pain in the left upper stomach area or left shoulder area as these may be signs of an enlarged or burst (ruptured) spleen.
  • Mozobil may harm the unborn child when administered to a pregnant woman. Scientific studies have shown that Mozobil causes harm to unborn animals. The safety of Mozobil in pregnant women has not been established in clinical trials. If you are of childbearing potential you should be advised to avoid becoming pregnant while receiving treatment with Mozobil. If this drug is used during pregnancy, or if you become pregnant while taking this drug, you should be apprised of the potential hazard to the unborn child.
  • The most common adverse reactions (occurring in greater than or equal to 10% of patients) during HSC mobilization and apheresis were: diarrhea (37%), nausea (34%), tiredness (fatigue) (27%), injection site reactions (34%), headache (22%), pain in your joints (arthralgia) (13%), dizziness (11%), and vomiting (10%).

Please see full Prescribing Information

Prepare for an Autologous Stem Cell Transplant

Learn more about the autologous stem cell transplant process and what to expect with our easy-to-follow step-by-step guide.

Download guide (PDF)

Important Safety Information
Severe, life-threatening allergic reactions (anaphylaxis) can happen in people who take Mozobil. Tell your doctor right away if you experience hives (itchy raised bumps), eye swelling, or trouble breathing.

  • Indication

    Mozobil (plerixafor injection) is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM).

    Important Safety Information for Mozobil (plerixafor injection)

    • Severe, life-threatening allergic reactions (anaphylaxis) can happen in people who take Mozobil. Tell your doctor right away if you experience hives (itchy raised bumps), eye swelling, or trouble breathing.
    • Mozobil is not intended for hematopoietic stem cell transplantation (HSCT) mobilization and collection in patients with leukemia.
    • Mozobil in combination with G-CSF increases circulating white blood cells (WBCs). Your WBC counts will be monitored.
    • Thrombocytopenia (a decrease in the number of platelets circulating in the blood) has been observed in patients receiving Mozobil. Your platelet counts will be monitored.
    • Cancer cells may be released from the bone marrow and subsequently collected along with your stem cells during apheresis. The potential effects of infusing cancer cells during your transplant have not been well-studied.
    • Your spleen may be examined if you experience pain in the left upper stomach area or left shoulder area as these may be signs of an enlarged or burst (ruptured) spleen.
    • Mozobil may harm the unborn child when administered to a pregnant woman. Scientific studies have shown that Mozobil causes harm to unborn animals. The safety of Mozobil in pregnant women has not been established in clinical trials. If you are of childbearing potential you should be advised to avoid becoming pregnant while receiving treatment with Mozobil. If this drug is used during pregnancy, or if you become pregnant while taking this drug, you should be apprised of the potential hazard to the unborn child.
    • The most common adverse reactions (occurring in greater than or equal to 10% of patients) during HSC mobilization and apheresis were: diarrhea (37%), nausea (34%), tiredness (fatigue) (27%), injection site reactions (34%), headache (22%), pain in your joints (arthralgia) (13%), dizziness (11%), and vomiting (10%).

    Please see full Prescribing Information